Earnings Call · Q2 FY2023·2023-08-14

Q2 21EPS n/a·Rev n/aQ1 21EPS n/a·Rev n/aQ4 20EPS n/a·Rev n/aQ2 20EPS n/a·Rev n/a⚠ consensus missing

NRX Pharmaceuticals, Inc. NRXPW

Matthew Duffy — Chief Business Officer

Steve Willard — Chief Executive Officer

Jonathan Javitt — Chief Medical Officer

Seth Voorhees — Chief Financial Officer

0.0%1d on move date+1.2% vs SPY3d+13.1%5d−26.6%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NRXPW calls or request research access.

More NRXPW calls Browse calls Request research access